GLOBAL CELL THERAPY MANUFACTURING EQUIPMENT MARKET (2026 - 2030)

In 2025, the Cell Therapy Manufacturing Equipment Market was valued at approximately USD 3.45 billion. It is projected to grow at a CAGR of around 14.6% during the forecast period of 2026–2030, reaching an estimated USD 6.82 billion by 2030.

Global Cell Therapy Manufacturing Equipment Markets turn out to be the ecosystem of the specific systems that are used to modify the living cells into treatment products during the multi-stage production procedures. It covers instruments that allow isolating, growing, altering, storing, and ultimately preparing cells to be utilized by patients. Precision, sterility, and reproducibility are key attributes of success in the market, which is a critical layer of the cell therapy value chain. It is not only influenced by technological innovation but also by the changing requirements of the clinical and commercial scale production.

The market encompasses capital equipment that is used in cell processing processes, including upstream handling, downstream preparation, and storage. It does not consider consumables, reagents, contract services, or the therapeutic products themselves, but only equipment sales. This limit provides a demarcation in the attribution of revenues and prevents overlaps with other neighboring markets. Customers usually consider the consistency of performance, integration, and readiness to comply with the systems, as opposed to the specifications taken separately.

The situation is changing to an integrated, automated, and closed landscape as opposed to a fragmented, manual landscape. Therapy in its non-clinical phase is increasingly often standardized and scalable. The emergence of allogeneic methods and growing commercial grants are driving the demand for high throughput and process reliability. Meanwhile, the complexity of operation is rising, and it needs much tighter control between the interlinked steps.

Key Market Insights

• There is an increase in the share of advanced therapies between 11% and 21% in pipelines.
• More than 20% of EBITDA is invested in digital biopharma transformation fabrication.
• Today, biopharma firms that report full maturity of digital manufacturing only amount to 20% of the total.
• The use of AI increased the efficiency of processes among 43% of manufacturers in the life sciences.
• Almost 48% of executives forecast manufacturing risks to redefine strategies.
• The digitalization of cell therapy manufacturing is becoming dependent on orchestrating systems based on clouds.
• The investments in regenerative medicine are expected to be in excess of $27 billion throughout the world.
• Automation can minimize the number of manual intervention steps in workflows by more than 30 percent.
• The use of a closed system greatly reduces the risks of contamination in the cell processing environment.
• Digital transformation is a catalyst for a quicker batch launching schedule in sophisticated therapy creation.
• Asia-Pacific facilities are growing at a fast pace due to significant investments in biomanufacturing facilities.
• The rising outsourcing need is contributing to the growth of manufacturing capacity through CDMOs in the world market.
• The digitization of workflow enhances compliance with multi-site manufacturing.

Research Methodology

Scope & Definitions

• Covers global sales of cell therapy manufacturing equipment (processing, expansion, separation, fill-finish, cryopreservation).
• Excludes consumables, reagents, services, and therapy revenues.
• Geography: global with regional splits; timeframe: historical + forecast period defined in-report.
• Segmentation follows MECE principles; clear data dictionary ensures uniform definitions.
• Double counting prevented via single transaction layer and supplier-level mapping.

Evidence Collection (Primary + Secondary)

• Primary interviews across OEMs, CDMOs, biopharma firms, and research institutes.
• Validation through executive interviews, procurement heads, and technical experts.
• Secondary sources include company filings, investor presentations, patents, and verified databases.
• References include relevant regulators/standards bodies/industry associations specific to Cell Therapy Manufacturing Equipment Market (named in-report).
• All key claims supported by verifiable, source-linked evidence within the report.

Triangulation & Validation

• Market sizing via bottom-up (company revenues) and top-down (industry benchmarks).
• Cross-verification against financial disclosures and shipment data where available.
• Conflicting inputs resolved through weighted source credibility and consensus modeling.
• Iterative validation with industry experts ensures accuracy and bias control.

Presentation & Auditability

• Data presented with transparent assumptions, segmentation logic, and calculation models.
• Each insight traceable to cited, verifiable sources for audit readiness.
• Structured outputs enable easy benchmarking, replication, and decision-grade use.

Cell Therapy Manufacturing Equipment Market Drivers

Quickening Cell Therapy Pipeline and Clinical Translation.

The market is also being intensely motivated by the ongoing boom of cell therapy pipelines in oncology, rare diseases, and regenerative medicine. There is an increasing trend of treatments that are not in the preclinical phase of their development going to late-stage clinical trials and, in a few cases, commercial development. This shift is not merely a growing demand; it is altering the nature of the equipment in demand. Small, flexible setups are common in starting programs, but as programs scale, a distinct transition is made to scalable, standardized platforms that are able to maintain a consistent output.

Move to More Automation and a Closed System.

Manufacturers are reacting by embracing semi-automated and fully automated systems that minimize the involvement of human beings and enhance reproducibility. Special focus is put on closed systems, which reduce contact with the outside world, which proves critical in preserving the integrity of the products. This change is, however, not simply a technological one—it is a strategic change. Organizations are coming to realize that automation is not only about efficiency but also about scale, failure rates, and regulatory compliance.

Growing Importance of Outsourcing and Specialist Manufacturing Infrastructure.

Another important driver that is influencing the market is the increased dependence on contract development and manufacturing organizations. Not every developer of the therapy has the means and know-how to construct and manage the complex manufacturing plants. Consequently, they are resorting to specialized partners, which have the ability to offer end-to-end production.

Cell Therapy Manufacturing Equipment Market Restraints

High capital costs and unpredictable scale economics are the long-term irritants in the market. Most systems can perform very well at the early stages, but fail on the commercial transition. Operational complexity is caused by process variability, low levels of standardization, and inter-equipment layer integration. The regulatory demands keep changing to impose a compliance burden and extend the process of validation.

Cell Therapy Manufacturing Equipment Market Opportunities

The Global Cell Therapy Manuf. The equipment market is providing new opportunities as developers drive towards scalable and standardized production. The increase in the need to have automated and closed systems implies the possibilities of equipment enhancing consistency and minimizing the risk of contamination. Growth of commercial production promotes the necessity to have high-throughput platforms, whereas new markets invest in domestic production. Innovation is also progressing faster through strategic collaborations between equipment and therapy developers.

How this market works end-to-end

1. Therapy Type Selection

Therapy developers define whether the process is autologous or allogeneic, which shapes equipment needs.

2. Cell Processing Setup

Cell collection and initial processing systems are selected to isolate and prepare starting material.

3. Cell Expansion Systems

Expansion platforms, often bioreactors, are chosen based on scale, yield, and control requirements.

4. Cell Separation Stage

Separation and sorting equipment refine cell populations to meet therapy specifications.

5. Fill-Finish Preparation

Fill-finish systems prepare final doses in sterile, controlled environments.

6. Cryopreservation & Storage

Cryopreservation equipment enables storage, transport, and inventory management.

7. Automation Level Choice

Teams decide between manual, semi-automated, or fully automated closed systems.

8. Scale Transition Planning

Scale shifts from clinical to commercial manufacturing, requiring different throughput and reliability.

9. Workflow Integration

Equipment integration across steps becomes critical to avoid process bottlenecks.

10. End-User Validation

End users, including biopharma firms and CDMOs, validate systems against regulatory and operational standards.

What matters most when evaluating claims in this market

The decision lens

1. Define your therapy pathway
   Check whether your process is autologous or allogeneic and align equipment accordingly.
2. Map end-to-end workflow
   Ensure all steps from processing to cryopreservation are covered without gaps.
3. Evaluate scale transition
   Compare how equipment performs from clinical to commercial scale, not just initial setup.
4. Assess automation fit
   Match automation level to your operational maturity and workforce capability.
5. Validate integration
   Ask vendors how their systems connect with upstream and downstream processes.
6. Stress-test vendor claims
   Request multi-batch data, real-world use cases, and failure scenarios.
7. Align with end-user needs
   Different users, such as CDMOs or hospitals, require different flexibility and throughput.

The contrarian view
Many buyers assume automation is always better. It is not. Over-automation can lock processes too early and increase cost without improving outcomes. Another common mistake is treating clinical-scale success as proof of commercial viability. These are different problems.

Vendors often present “closed systems” that still rely on manual interventions between steps. This creates hidden contamination risks.

Double counting also occurs when buyers evaluate systems independently rather than as part of a workflow. A high-performing bioreactor means little if fill-finish becomes the bottleneck.

One-size-fits-all solutions rarely work. Autologous workflows demand flexibility, while allogeneic setups prioritize scale and consistency. Mixing these assumptions leads to poor investment decisions.

Practical implications by stakeholder

• 1. Biopharmaceutical & Biotechnology Companies
• Prioritize scalable platforms that align with pipeline growth
• Avoid locking into rigid systems too early
  2. Contract Development & Manufacturing Organizations (CDMOs)

• Invest in flexible equipment to serve multiple clients
• Balance automation with adaptability across projects
  3. Academic & Research Institutes

• Focus on modular systems for experimentation
• Avoid over-investing in commercial-scale equipment
  4. Hospitals & Cell Therapy Centers

• Choose user-friendly, compact systems
• Emphasize reliability over advanced automation
  5. Equipment Manufacturers

• Differentiate through integration, not just performance
• Provide real-world validation, not lab-only data

GLOBAL CELL THERAPY MANUFACTURING EQUIPMENT MARKET

Cell Therapy Manufacturing Equipment Market Segmentation

Cell Therapy Manufacturing Equipment Market – By Equipment Type

• Introduction/Key Findings
• Cell Processing Systems
• Cell Expansion & Bioreactor Systems
• Cell Separation & Sorting Equipment
• Fill-Finish Equipment
• Cryopreservation Equipment
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Cell Processing Systems, with the highest share of 28%, is the backbone of the operations in the entire workflow, and Cell Expansion & Bioreactor Systems, with the highest growth rate of 24 percent, is the most expanding one because of the rising scale needs. Separation equipment contains 18%. fill-finish 13%. cryopreservation, 11. and others 6.

The highest growth is also seen in Cell Expansion & Bioreactor Systems, with 24% growth since there is the increasing demand for scalable and controlled conditions, whereas Cell Processing Systems, with 28%, continue to be the dominant ones because of the universal applications across both initial and commercial manufacturing configurations worldwide.

Cell Therapy Manufacturing Equipment Market – By Therapy Type

• Introduction/Key Findings
• Autologous Cell Therapy Equipment
• Allogeneic Cell Therapy Equipment
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Cell Therapy Manufacturing Equipment Market – By Scale of Operation

• Introduction/Key Findings
• Preclinical & Clinical Scale Manufacturing
• Commercial Scale Manufacturing
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Cell Therapy Manufacturing Equipment Market – By Level of Automation

• Introduction/Key Findings
• Manual Systems
• Semi-Automated Systems
• Fully Automated & Closed Systems
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Semi-automated systems, with the highest share of 38%, are the most flexible and efficient, with fully automated and closed systems at 34% and the highest growth rate of 17.5%, respectively, because of the advantage of sterility and reproducibility. Manual systems have 20 percent, and others have 8 percent.

Fully automated systems and closed systems are the most rapidly growing, with 34 and 38 percent growth, with the help of contamination control benefits and lower costs of start-up and adaptability to various production settings.

Cell Therapy Manufacturing Equipment Market – By End User

• Introduction/Key Findings
• Biopharmaceutical & Biotechnology Companies
• Contract Development & Manufacturing Organizations (CDMOs)
• Academic & Research Institutes
• Hospitals & Cell Therapy Centers
• Others
• Y-O-Y Growth Trend & Opportunity Analysis

Cell Therapy Manufacturing Equipment Market – Regional Analysis

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

North America takes up the largest share of 39% due to the high manufacturing infrastructure, and Asia Pacific, Europe, South America, and the Middle East and Africa share 26%, 22%, 7%, and 6%, respectively.

Asia Pacific, with a growth of 26, and North America, at 39, are the fastest growing at this stage due to increasing manufacturing investments and infrastructure in the countries and the existing facilities, regulatory maturity, and ongoing cell therapy manufacturing ecosystems, respectively.

Latest Market News

Mar 19, 2026. One of the strongest biopharma leaders declared an innovation cell therapy production plant in Shanghai, investing more than USD 1 billion in the development of automated manufacturing and the rapid growth of equipment demands in the region.

Jan 08, 2026. A large equipment vendor partnered with a multinational CDMO to develop a strategic alliance to develop fully automated closed systems, aiming at reducing 25 percent of the number of manual steps in clinical scale processes.

Oct 14, 2025. A bioprocessing technology company introduced a second-generation bioreactor platform, which could expand from 2L to 200L and change cell expansion efficiency by about 40% in preliminary commercial operations.

Jun 27, 2025. One of the world's leading life sciences companies has successfully acquired one of the cell processing technology startups in a USD 275 million transaction, which has enhanced its hold on automated cell handling systems.

Mar 11, 2025. Multi-site validation program. The multi-site validation program started as a consortium of academic institutes and biotech firms of more than 50 manufacturing units to standardize closed-system workflows to minimize batch variability.

Dec 05, 2024. One of the CDMOs extended its footprint of cell therapy manufacturing with 120,000 square feet of cleanroom space and nearly 35% equipment installation capacity.

Aug 22, 2024. An equipment supplier in the U.S. had entered into a long-term supply contract with a European biotech firm to supply more than 150 automated units of cell processors to several facilities.

Feb 16, 2024. A regulatory agency presented new standards on the manufacturing of advanced therapies, and equipment vendors revised their systems to enhance their ability to comply with the standards and trace the production process.

Key Players

1. Thermo Fisher Scientific Inc.
2. Sartorius AG
3. Danaher Corporation
4. Merck KGaA
5. Lonza Group AG
6. Eppendorf AG
7. Getinge AB
8. Cytiva (Danaher Corporation)
9. Miltenyi Biotec
10. Fresenius Kabi AG
11. Terumo Corporation
12. BD (Becton, Dickinson and Company)
13. Bio-Techne Corporation
14. Avantor, Inc.
15. Corning Incorporated